Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 5/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.32 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.32 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.32 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.32 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.32 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.32 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.32 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.32 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.32 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.32 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.32 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.32 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.32 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23344168 | 1.00 | GPR139 (0.34) | GPR139CA1CA2PSMB5PSMB1 | |
| SCHEMBL28921949 | 0.92 | CA1 (0.32) | GPR139CA1CA2PSMB5HDAC4 | |
| SCHEMBL12846265 | 0.92 | HDAC4 (0.38) | CA1CA2HDAC4CCR2 | |
| SCHEMBL12846262 | 0.90 | TTK (0.33) | CA1CA2HDAC4 | |
| Fluralaner SCHEMBL8515337 | 0.89 | CA1 (0.32) | CA1CA2HDAC4 | |
| Fluralaner SCHEMBL8513367 | 0.89 | CA1 (0.32) | CA1CA2HDAC4 | |
| Fluralaner SCHEMBL29399660 | 0.89 | CA1 (0.32) | CA1CA2HDAC4 | |
| Fluralaner SCHEMBL121934 | 0.89 | CA1 (0.32) | CA1CA2HDAC4 | |
| Fluralaner SCHEMBL29362559 | 0.89 | CA1 (0.32) | CA1CA2HDAC4 | |
| SCHEMBL737408 | 0.89 | EGLN1 (0.36) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20210061775-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2021-03-04 | — | — | US | disclosed |
| EP-3473101-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS FOR FELINES | Intervet International B.V. (NL) | 2019-04-24 | — | — | EP | disclosed |
| US-20180155301-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20160332975-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20150111936-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2545777-A1 | Isoxazoline compositions and their use as antiparasitics | Intervet International B.V. (NL) | 2013-01-16 | — | — | EP | disclosed |
| US-20110059988-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INTERNATIONAL B.V. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332975-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | GPR139 3363/4885CA1 1771/4885CA2 651/4885 |
| US-20210061775-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | GPR139 3363/4885CA1 1771/4885CA2 651/4885 |
| US-20180155301-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | GPR139 3363/4885CA1 1771/4885CA2 651/4885 |
| US-20150111936-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, EPX | GPR139 3421/4885CA1 1649/4885CA2 595/4885 |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | GPR139 3363/4885CA1 1771/4885CA2 651/4885 |
| US-20110059988-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, AADAC | GPR139 3401/4885CA1 1922/4885CA2 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.